Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, shared a post on X by Roger Li, Urologic Oncologist at Moffitt Cancer Center, adding:
“Great initiative led by Ashish M. Kamat, Roger Li, to tackle bladder toxicities with intravesical, surgery, radiation, and systemic therapies. Unmet need to develop new urology-specific toxicity grading criteria to complement CTCAE and develop specific PROs across different treatments.”
Quoting Roger Li’s post:
“Ashish M. Kamat kicking off IBCG 2025.
Look forward to the discussions on two exciting topics
- Biomarkers in UC
- Bladder-related toxicity.”
More posts featuring Shilpa Gupta and Roger Li.
